At Chicago's McCormick Place Convention Center this past weekend, more than 44,000 oncology professionals gathered to hear three results that oncologists are already calling the most consequential in years: a drug that nearly doubled survival in metastatic pancreatic cancer, a genomic test that spares two-thirds of breast cancer patients from chemotherapy, and a new immunotherapy molecule that beat standard treatment head-to-head in squamous lung cancer. For patients and physicians, all three carry immediate, concrete implications — one is already in expanded access, one is commercially available now, and one reached an FDA filing milestone months ago.
The pancreatic cancer breakthrough centers on daraxonrasib, an oral pill that finally cracked what researchers spent four decades calling "undruggable" — the KRAS gene, mutated in roughly 90% of pancreatic cancer cases. In the phase III RASolute 302 trial presented by Revolution Medicines, daraxonrasib cut the risk of death by 60% compared with standard chemotherapy in patients who had already received one prior treatment line. Median overall survival reached 13.2 months for those taking daraxonrasib, nearly double the 6.7 months for the chemotherapy group — a difference with a p-value below 0.0001. The 500-person global trial enrolled patients from North America, Europe, and Asia. "This is the first RAS inhibitor evaluated in a large, randomized trial for patients with pancreatic cancer," said Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute and the trial's principal investigator, prompting a standing ovation in the packed auditorium.
What makes this result particularly significant is its breadth. Daraxonrasib worked regardless of which specific RAS mutation a patient carried — even in rare cases where the gene was not mutated at all. That means physicians don't need to screen for a specific KRAS subtype before prescribing, a major practical advantage. The drug also produced fewer severe side effects than chemotherapy: 43.6% of daraxonrasib patients experienced grade 3 or higher adverse events compared with 57.5% in the chemotherapy group.
The FDA's actions reflect the urgency felt around this result. The agency granted daraxonrasib Breakthrough Therapy and Orphan Drug designations, and in May issued a safe-to-proceed letter for an expanded access program — meaning eligible patients outside clinical trials can now receive the drug through requests initiated by licensed physicians. Revolution Medicines announced it intends to submit a new drug application under the FDA's Commissioner's National Priority Voucher program, which compresses the standard review timeline from ten months to six months.
Yet important uncertainties remain. The drug's price has not been set, and targeted cancer therapies historically cost tens of thousands of dollars monthly — a concern especially for the majority of cancer patients who receive care in community settings rather than large university hospitals. Daraxonrasib is not yet approved by any regulatory authority, and researchers are already studying how cancers may develop resistance. Still, for patients with metastatic pancreatic cancer — a disease that kills roughly 50,000 Americans every year — the arrival of a drug that addresses the genetic underpinning of their disease represents a long-awaited turning point.